Methods: We conducted a prospective observational cohort study of 790 healthy first-or second-degree female relatives of patients with documented Graves or Hashimoto disease in the Netherlands. Baseline assessment included measurement of serum thyrotropin (TSH), free thyroxine (FT4), and thyroid peroxidase (TPO) antibody levels as well as evaluation for the presence and levels of Yersinia enterocolitica antibodies. We also gathered data on family background, smoking habits, use of estrogen medication, pregnancy, and exposure to high levels of iodine. In follow-up, thyroid function was investigated annually for 5 years. As main outcome measures, termed events, we looked for overt hypothyroidism (TSH levels >5.7 mIU/L andFT4 levels <0.72 ng/dL) or overt hyperthyroidism (TSH levels <0.4 mIU/L and FT4 levels >1.56 ng/dL).

Results:
The cumulative event rate was 7.5% over 5 years. The mean annual event rate was (8) (9) (10) , high (11) (12) (13) (14) (15) , and very high (16) (17) (18) (19) (20) (21) 
1.5%. There were 38 hypothyroid and 13 hyperthyroid events. Independent risk factors for events were baseline findings for TSH and TPO antibodies in a level-dependent relationship (for TSH the risk already starts to increase at values >2.0 mIU/L) and family background (with the greatest risk attached to subjects having 2 relatives with Hashimoto disease
Introduction
Autoimmune thyroid disease (AITD) occurs more often in women than in men and frequently runs in families. Siblings of patients with AITD are clearly at risk, as evident from a sibling risk ratio (λs) ranging from 5.9 to higher than 10 (λs represents the ratio of the risk for developing AITD in a sibling of a patient with AITD beyond the risk for AITD present in the general population). [1, 2] Twin studies suggest that genetic factors account for about 70% of the risk of contracting AITD and that environmental factors contribute about 30% to the risk. [3] [4] [5] [6] Subjects with family members who have AITD are obviously at increased risk for AITD. It is thus understandable that a frequently asked question by patients with AITD is "Will mydaughter ormysister also get this disease?" The physician is likely to answer that indeed the risk in family members -especially in women-is increased, but the physician will have difficulties in giving a more precise estimate of the risk. To obtain a quantitative risk estimate, we undertook a prospective observational study in a cohort of healthy first-or seconddegree female relatives of patients with AITD who were observed for 5 years. The baseline characteristics of this cohort have been reported previously. [7] We aimed to design a simple score to predict the risk for developing overt hypothyroidism or hyperthyroidism based on the results of thyroid function tests, family history, and exposure to some environmental insults at study entrance.
METHODS
Study design and participants
The study was approved by the institutional review board of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. The original cohort consisted of 803 healthy female subjects who had at least 1 first-or second-degree relative with documented autoimmune hyperthyroidism or hypothyroidism. All subjects were in self-proclaimed good health with no history of thyroid disease and were between 18 and 65 years old. The autoimmune nature of the thyroid disease in the subjects' relatives was ascertained by letters from their treating physicians. Results of thyroid function tests revealed overt hypothyroidism in 10 subjects and overt hyperthyroidism in 3 subjects, leaving 790 subjects to be included in the present study. [7] All subjects were seen at our institution. 
Laboratory measurements
Serum TSH and FT4 levels were measured using time-resolved fluoroimmunoassay (Delphia, 
Statistical analysis
Statistical analysis was carried out with the SPSS software, version 10 (Chicago, Illinois 
Results
Baseline characteristics of the cohort are summarized in Table 1 . All participants had serum FT4 concentrations within the reference range, but 19 subjects had subclinical hypothyroidism (2.4%), and 13 subjects had subclinical hyperthyroidism (1.6%). With respect to family background, 608 of the 790 participants came from families with 2 proven patients with AITD (77%); both of these first-or second-degree relatives in each case had either the same AITD (either Graves hyperthyroidism or Hashimoto hypothyroidism for both relatives), or one had Graves disease, and the other had Hashimoto disease. In 182 of the 790 participants, we obtained proof of AITD in only 1 first or second-degree relative (23%).
Although each of these participants reported 2 relatives with thyroid disease, information obtained from the treating physician of the second relative indicated either non-AITD (eg, nontoxic goiter or thyroid cancer) or hypothyroidism or hyperthyroidism of unspecified cause, and these cases were labeled as indeterminate. Seven participants used antihypertensive drugs, and 1 used oral antidiabetic agents; none used lithium salts or amiodarone. During the 5-year observation period, 136 of the 790 participants were lost to follow-up (17.2%), the loss occurring rather evenly over the whole study period, with an average annual loss of 27 participants. Characteristics of the dropouts were similar to those of the whole group (data not shown). aFor the definition of normal thyroid function, see the "Methods" section. bData are reported as percentage (number of applicable subjects/total number of possible subjects); the overall event rate for all subjects was 6.5% (51 of 790). cBy Cox regression analysis. dExcluding the lowest TSH category (_0.4 mIU/L). ePresence and type of AITD in 2 of the subject's first-or second-degree relatives.
Occurrence of events
serum TSH level was 0.02 (<0.01 to 0.13) mIU/L, and for FT4, it was 3.2 (1.6 to >5.4) mg/dL. At baseline, 2 of the 13 subjects with hyperthyroidism had serum TSH levels lower than 0.4 mIU/L; [9] had TPO antibody concentrations higher than 100 kU/L; and none had TBII levels higher than 12 U/L. Hypothyroid events occurred more often in subjects having 1 Table 2 ). Figure 1 depicts the cumulative event rate in the population at risk, which was 7.5% over 5 years. The mean annual event rate was 1.5%. 
Risk factors for events
Predictive score for events
A simplified model was obtained from the logistic regression model by putting weights to individual risk factors proportional to their relative risks. This model allowed the calculation of a predictive score called theTHEA score (Table4).
The operational value of the THEA score was evaluated by comparison of the observed and expected event rates ( Table 5 ). The good agreement between both event rates is taken as a measure for the validity of the THEA score. Event rates increased significantly as the THEA score increased (P<.001 for trend by χ² analysis) (Figure 2) . peroxidase; TSH, thyrotropin. aFor the definition of normal thyroid function, see the aFor the definition of normal thyroid function, see "Methods" section.
the "Methods" section. bData are reported as percentage (number of applicable subjects/total number of possible subjects).
We observed in our at-risk female population a cumulative event rate of 7.5%, with an annual incidence rate of 1.5%. Overt hypothyroidism occurred in 38 subjects, and overt hyperthyroidism in 13 subjects during the 5-year follow-up of the 790 participants. The hypothyroidism incidence rate in our population was 9.6/1000/y; the hyperthyroidism al, [10] and in the retrospective Tayside study by Flynn et al. [11] Both the Whickham and the Tayside studies were conducted in England, a country considered to be iodine sufficient (mean urinary iodine excretion level, 141 µg/L). [12] The incidence rates of hypothyroidism in these 4 areas were 0.44, 0.61, 3.5, and 4.98 per 1000 women per year, respectively.
Incidence rates of hyperthyroidism were 1.49, 1.02, 0.80, and 0.77 per 1000 women per year, respectively. To convert iodine to nanomoles per liter, multiply by 7.880. These epidemiologic data support the notion that higher levels of dietary iodine decrease the incidence of hyperthyroidism at the expense of an increased incidence of hypothyroidism.
The Netherlands is considered to be a country of dietary iodine sufficiency, with a median Figure 2 . The Thyroid Events Amsterdam (THEA) score used to predict hypothyroid and hyperthyroid events over 5 years in a euthyroid cohort of 790 women with first-or second-degree relatives with proven autoimmune thyroid disease. Event rates increased significantly, as measured by the χ² test, as the THEA score increased (P<.001 for trend).
urinary iodine excretion level of 154 µg/L. [13] Our incidence figures are therefore best compared with those in the United Kingdom: in our at-risk female population, the incidence rate of overt hypothyroidism is 1.9 to 2.7 times higher than that in the general female population in the United Kingdom, and the incidence rate of hyperthyroidism is 4.1 to 4.3 times higher. These figures once again demonstrate that subjects with a family history of AITD are at increased risk for thyroid disease. The risk in siblings of parents with AITD is much higher than that observed in the present study (with reported λs as high as 11.6 for Graves disease and 28.0 for Hashimoto thyroiditis). [2] This finding is understandable because relatives with AITD in our study could be children, brothers, sisters, parents, grandparents, uncles, or aunts of the participants. Our figures thus fit nicely between the lower risk in the general population and the higher risk in siblings. In the present study, we found that independent risk factors are serum TSH level (increased risk at TSH values <0.4 mIU/L and >2.0 mIU/L, still within the reference range), high TPO antibody concentration, and presence of a family history of AITD (with the greatest risk attached to subjects having 2 relatives with Hashimoto disease). These findings are in perfect agreement with the prospective Whickham study, [10] which reported that the risk to develop hypothyroidism sharply increased at TSH levels above 2 mIU/L, independently of TPO antibody levels.
The agreement in these findings underscores the notion that TSH levels between 0.4 and 2.0 mIU/L are associated with optimal thyroid health. [14, 15] The progressively increasing risk with increasing TPO antibody concentrations, independent of TSH levels, has also been observed in the Whickham study. [10] Advancing age is associated with a higher concentration of TPO antibodies, [10] which likely explains why age in our study was not an independent risk factor. In the Whickham study, the agespecific hazard rates for the development of hypothyroidism (but not for hyperthyroidism) sharply increase when the patients are older than 60 years. [10] In our study, the trend of a higher event rate in older age was nonsignificant, probably owing to the small number of subjects in the age group 60 to 65 years (only 30 subjects). In the Whickham study, [10] . If the THEA score is higher, reassessment after 1 year might be warranted. The THEA score might be very useful for young women of AITD families who want to become pregnant in the next few years. [16] Screening seems to be indicated for these women in view of the high abortion rate associated with the presence of TPO antibodies. The abortion rate can be lowered by treatment with levothyroxine. [17] Our study has several limitations. The THEA score is derived from a female population and may be not applicable to men. Although a large sex difference is unlikely, the score should be validated in a male population. Prediction of events by the THEA score is restricted to a time span of 5 years, but undoubtedly many more events will occur after that period. In clinical practice, reassessment of the THEA score after 5 years might be indicated. Another important limitation of our study is the relatively low number of events, especially hyperthyroid events, which probably renders the THEA score less accurate.
The small number of observed events may raise concern about possible overfitting of our model. Consequently, there is a need to validate the THEA score in other populations.
Finally, the precise genetic background in 182 of the 1580 relatives could not be ascertained (11.5%); an unknown proportion of these indeterminate relatives might still have Graves or
Hashimoto disease, thereby affecting the weights assigned to family background in the THEA score. This bias is likely to be small in view of its limited contribution to the maximum THEA score. The uncertainty is acceptable because it reflects the reality of day-today practice in which it is not always possible to determine with certainty the autoimmune nature of thyroid disease in family members. Inclusion of indeterminate relatives in our study permits application of the THEA score also in subjects with only 1 known relative with AITD.
